Project Number 3P01AG010435-16S1 Agency/Funding Organization NIA Funding Year 2008 View Full Project Details for GENE THERAPY FOR ALZHEIMER'S DISEASE Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 3. Drug Discovery (small molecules and biologics) q. Epigenetic Regulators Researcher and Organization Principal Investigator GAGE, FRED H Principal Investigator First Name FRED H Principal Investigator Last Name GAGE Awardee Organization SALK INSTITUTE FOR BIOLOGICAL STUDIES Awardee State California Contact PI Country United States Project Detail FY Overall Cost $250,000 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official BUCKHOLTZ, NEIL Related Resources Repository [AlzPED] Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease. [AlzPED] Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. [AlzPED] A Neuroprotective Brain-penetrating Endopeptidase Fusion Protein Ameliorates Alzheimer Disease Pathology and Restores Neurogenesis [AlzPED] Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. [AlzPED] Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation.
